As the U.S administers millions of vaccines nationwide virus mutations could cause problematic, making Johnson & Johnsons one does vaccine a potential silver bullet

Keep your eye on is Avalon GloboCare (NASDAQ:AVCO)

20

In CNBC’s recent article” U.S. potentially facing ‘perpetual infection’ of Covid in spring as new variants spread, warns Dr. Scott Gottlieb” that researchers at Ohio State found a new Covid strain in the U.S that scientist have never seen before. https://www.cnbc.com/2021/01/14/us-potentially-facing-perpetual-infection-of-covid-says-gottlieb.html   

The United States has sustained a gut-wrenching 8,400 deaths over the past two days and nearly 40,000 in less than two weeks of 2021,according to a CNBC analysis of Johns Hopkins data. The pandemic is, on average, killing more than 3,300 Americans a day.

Gottlieb told host Shepard Smith that he is “encouraged” by Johnson & Johnson’s (NYSE: JNJ) one-dose vaccine and “confident” in the company’s ability to scale its manufacturing to help bolster the Covid vaccine rollout across the U.S. 

As the war against COVID-19 wages on there are a large number of Bio-Tech players racing to get an effective vaccine to market and with the new strands there is a concern with who’s will be effective.  Another company to keep your eye on is Avalon GloboCare (NASDAQ:AVCO) who are using a proprietary S-Layer  “surface layer” technology to develop an intranasal vaccine that attaches to the mucosal membrane CEO Dr. David Jin pointed out. “We see our vaccine candidate as a complement to any injectable vaccines in clinical trials, because it could provide first-line immune protection at the virus’s entrance site”. Adding a coat of an S-layer onto solid surfaces can greatly improve the function of a therapeutic, vaccine, or device. The S-layer allows enhanced efficiency and interaction of targeted proteins and molecules for better function.

Avalon GloboCare is in the process of establishing a state-of-the-art research facility, the Christian Doppler Laboratory, located on the BOKU campus in Vienna, Austria, under the scientific leadership of Professor Eva-Kathrin Ehmoser, the Head of BOKU’s Institute for Synthetic Bioarchitectures and Professor Uwe Sleytr, a member of the Austrian Academy of Sciences. In connection with the new facility, Avalon and BOKU have signed a Memorandum of Understanding (MOU) to jointly apply for a matching research grant from the prestigious Christian Doppler Laboratory Foundation. Avalon also has research being done in MIT (Massachusetts Institute of Technology), the UNRLS (University of Natural Resources and life sciences in Australia), Weill Cornell Medicine in New York City and the Lu Daopei Medical Group in China, which has the country’s top ranked hematology and bone marrow transplant program 

In the December 2020 issue of Nature’s Biopharma Dealmakers, Avalon’s President and CEO, David Jin, M.D., Ph.D., highlighted Avalon’s ongoing scientific and clinical developments including a first-in-human trial of a mucosal, intranasal vaccine against SARS-CoV-2 that is planned for early 2021. Dr. Jin also described the company’s innovative, allogeneic mesenchymal stromal cell (MSC) therapy candidate, CB-MSC-1, which possess unique anti-inflammatory and immunomodulatory activities, as well as AVA-001, Avalon’s third-generation CAR T cell therapy that has shown robust activity in patients with relapsed, refractory B cell acute lymphoblastic leukemia in a Phase 1 trial (Avalon feature in Biopharma Dealmakers).

“We are excited and motivated to join forces with the researchers at BOKU to drive innovation. We have already begun a collaboration on the mucosal SARS-CoV-2 vaccine and are moving quickly to establish additional joint research endeavors to bring about innovative technologies and new medicines to patients,” said Dr. Jin.Avalon GloboCare, is a young, $100 million market cap company that has arguably some of the brightest minds in cell-based technology who have a competitive advantage with their “S-Layer” technology in a vaccine market that is expected to grow to approximately 93.billion by 2026 according to Forbes business . This small cap biotechnology company is working towards the goal of changing the way we fight the devastating affects of diseases that relentlessly attack our immune systems by using our own bodies against us. In the first quarter of 2020, Avalon GloboCare successfully completed a phase 1 first-in-human clinical study of AVA-001 in China for the treatment of relapsed refractory B cell acute lymphoblastic leukemia (R/R B-ALL). 90% of R/R B-ALL patients achieved complete remission with one dose and within one month of treatment, and then proceeded to a curative-intent allogeneic bone marrow transplant.  With more upcoming catalysts in Q4 2020 and early 2021, it is safe to say that there is a large potential upside in AVCO’s stock that currently trades at only $1.14.  The company has been well capitalized to date and has very clean cap table relative to its industry peers making it an attractive investment. 

About EmergingGrowth.com

Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  This report is not without bias. EmergingGrowth.com has motivation by means of either self-marketing or EmergingGrowth.com has been compensated by or for a company or companies discussed in this article. EmergingGrowth.com has been compensated two thousand five hundred dollars in consideration for its work with Avalon GloboCare Corp. through the date this was published. EmergingGrowth.com may or may not receive additional compensation, details about which can be found in our full disclosure, which can be found here, https://emerginggrowth.com/6282-723726/  You can easily loose money investing in highly speculative small cap stocks like the ones mentioned within. Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.